Nitrosamines in Drug Products: Where Are We Now?
Phil Koerner
Market Development Manager, Pharmaceuticals
Since 2018 when the presence of Nitrosamines was first reported in several ARB (angiotensin II receptor blocker) drugs, there has been increasing regulatory focus to mitigate the presence of these potential human carcinogens in drug substances and drug products.